Page last updated: 2024-10-24

carmustine and Emesis

carmustine has been researched along with Emesis in 26 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research Excerpts

ExcerptRelevanceReference
"Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens."9.27Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018)
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."9.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
" To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone."9.05Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982)
"To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation."7.83Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. ( Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L, 2016)
"A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug."7.75Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009)
"A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas."7.67Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986)
"Evidence supports olanzapine for prophylaxis of chemotherapy-induced nausea/vomiting (CINV) for highly emetogenic chemotherapy; however, most studies focus on solid malignancies and single-day regimens."5.27Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig ( Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C, 2018)
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."5.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
"We performed a clinical study of a triple-drug combination to evaluate its efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM (BCNU [carmustine]+etoposide+ARA-C [cytarabine]+melphalan) before hematopoietic stem cell transplantation (HSCT) by comparison with a historical control group of patients treated with dexamethasone (dex) and ondansetron or palonosetron."5.15A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. ( Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A, 2011)
"Both metoclopramide and prochlorperazine in combination with lorazepam and diphenhydramine offer good control of nausea and vomiting although the sedation and low risk for cardiac toxicity limit the regimen to an inpatient setting with close monitoring."5.08Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. ( Gilbert, CJ; Ohly, KV; Peters, WP; Rosner, G, 1995)
" To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone."5.05Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982)
"To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation."3.83Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. ( Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L, 2016)
"A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug."3.75Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009)
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks."3.67Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984)
"Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily."3.67Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987)
"A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas."3.67Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986)
"Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days."2.69Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000)
"Fifteen patients with germ cell neoplasms (9 testicular primary, 4 extragonadal, 2 adult teratoma syndrome) with features indicative of a poor prognosis were treated with chemotherapy followed by surgery."2.66Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms. ( Bukowski, RM; Montie, JE; Smith, GW, 1988)
" The dosage of CCNU was 100 mg/m2 p."2.65The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981)
"It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men."2.64Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976)
"Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT."1.30Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997)
" The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting."1.30Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-199014 (53.85)18.7374
1990's5 (19.23)18.2507
2000's2 (7.69)29.6817
2010's4 (15.38)24.3611
2020's1 (3.85)2.80

Authors

AuthorsStudies
Ahern, K1
Pham, J1
Sanderson, R1
Correia De Farias, M1
Walsh, K1
Clemmons, AB2
Orr, J1
Andrick, B1
Gandhi, A1
Sportes, C1
DeRemer, D1
Xiao, Y1
Liu, J1
Liu, YC1
Huang, XE1
Guo, JX1
Wei, W1
Clark, SM1
Schaack, L1
Garren, J1
DeRemer, DL1
Kota, VK1
Rzepecki, P2
Pielichowski, W2
Oborska, S2
Barzal, J2
Mlot, B2
Gawronski, K1
Wasko-Grabowska, A1
Stewart, DJ1
Benoit, B1
Richard, MT1
Hugenholtz, H1
Dennery, J1
Russell, N1
Peterson, E1
Grahovac, Z1
Belanger, G1
Maroun, JA1
Seigler, HF1
Lucas, VS1
Pickett, NJ1
Huang, AT1
DiBella, NJ1
Garfield, D1
Fink, K1
Anderson, P1
Speer, J1
Murphy, J1
Hansen, HH1
Selawry, OS1
Pajak, TF1
Spurr, CL1
Falkson, G2
Brunner, K1
Cuttner, J1
Nissen, NI1
Holland, JF1
Broun, GO1
Petruska, PJ1
Hiramoto, RN1
Cohen, HJ1
Gilbert, CJ1
Ohly, KV1
Rosner, G1
Peters, WP1
Hecht, JR1
Lembo, T1
Chap, L1
Yen, CC1
Hsieh, RK1
Chiou, TJ1
Liu, JH1
Fang, FS1
Wang, WS1
Tung, SL1
Tzeng, CH1
Chen, PM1
Dix, S1
Cord, M1
Howard, S1
Coon, J1
Belt, R1
Geller, R1
Slabý, J1
Trnený, M1
Procházka, B1
Klener, P1
Kessinger, A1
Lemon, HM1
Foley, JF1
Johnson, RO1
Metter, G1
Wilson, W1
Hill, G1
Krementz, E1
Costanzi, JJ1
Case, DC1
Ervin, TJ1
Boyd, MA1
Redfield, DL1
Bukowski, RM1
Smith, GW1
Montie, JE1
McClay, EF1
Mastrangelo, MJ1
Bellet, RE1
Berd, D1
Klein, DS1
Klein, PW1
Mahaley, MS1
Tormey, DC1
Gailani, S1
Leone, L1
Jorgensen, EO1
Malkasian, GD1
Webb, MJ1
Hahn, RG1
van Eden, EB1
Falkson, HC1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant[NCT04535141]Phase 391 participants (Actual)Interventional2020-08-18Completed
Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Re[NCT02635984]Phase 3108 participants (Actual)Interventional2015-11-30Completed
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287]Phase 3429 participants (Actual)Interventional2017-09-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Total Number of Rescue Medications Needed -Delayed

"The total number of rescue medications needed for breakthrough chemotherapy-induced nausea and vomiting were calculated, starting from the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for CINV prophylaxis." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).

Interventionnumber of rescue medication (Mean)
Usual Care0.47
Olanzapine1.17

Total Number of Rescue Medications Needed Acute

"The total number of rescue medications needed acute was calculated, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~The rescue medication is defined as documented administration of an anti-emetic agent other than those that are scheduled for chemotherapy-induced nausea and vomiting (CINV) prophylaxis." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)

Interventionnumber of rescue medication (Mean)
Usual Care0.08
Olanzapin0.10

Frequency of Nausea in the Acute Phase

"Starting with the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions. Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely in the first 24 hours following receipt of chemotherapy." (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration (Up to day 2)

,
InterventionParticipants (Count of Participants)
Met endpointDid not meet endpoint
Olanzapine441
Usual Care433

Frequency of Somnolence

The frequency of somnolence was determined as the number of patients who experienced somnolence based on Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The number of subjects has somnolence during the study period was counted. (NCT04535141)
Timeframe: Day 2-12

,
InterventionParticipants (Count of Participants)
subjects have somnolencesubjects do not have somnolence
Olanzapine142
Usual Care046

Number of Emesis Episodes in Delayed Phase

The number of emesis episodes in acute phase was defined as the number of subjects with no emesis, 1 emesis, and 2 or more emesis. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy ( Days 2-12).

,
InterventionParticipants (Count of Participants)
No emesis episodes1 emesis episode2 or more emesis episodes
Olanzapine3663
Usual Care3295

Number of Subjects Achieved Emesis Endpoint in Acute Phase.

: The number of subjects who did not experience emesis, starting from the first dose of highly or moderately emetogenic conditioning chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy. Met endpoint = 0 emesis. (NCT04535141)
Timeframe: End of day 1 following last chemotherapy administration. (Up to day 2)

,
InterventionParticipants (Count of Participants)
Met endpointDid not meet endpoint
Olanzapine450
Usual Care451

Number of Subjects Achieved Nausea Endpoint in the Delayed Phase.

"Nausea was assessed using subjects' responses to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea questions, starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy.~Scale: Never, Rarely, Occasionally, Frequently, Almost constantly.~The number of subjects who experienced never or rarely nausea were considered as met the endpoint while those who experienced occasionally, frequently or almost constantly were considered as not met the endpoint." (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2-12).

,
InterventionParticipants (Count of Participants)
Met endpointDid not meet endpoint
Olanzapine2718
Usual Care1927

Number of Subjects Achieving Minimal Nausea

"To determine the number of subjects achieving minimal nausea was defined as the frequency of participants responded to the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) nausea question In the last 24 hours, how often did you have nausea? as rarely or less Starting with the first dose of chemotherapy and continuing for one day after the last dose of highly or moderately emetogenic conditioning chemotherapy.~PRO-CTCAE of nausea scale includes categories: Never, Rarely, Occasionally, Frequently, Almost constantly To meet this endpoint the score reported for the Pro-CTCAE question for nausea frequency cannot exceed rarely and the score reported for the Pro-CTCAE question for nausea severity cannot exceed mild" (NCT04535141)
Timeframe: Day 2-12

,
InterventionParticipants (Count of Participants)
YesNo
Olanzapine2520
Usual Care1531

Safety Endpoint: Qtc Prolongation

Prolongation of corrected QTc interval graded as defined in Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Corrected QTc was calculated using Fredericia's Formula. Corrected QT interval (QTc) = QT interval / (60/Heart rate)^0.33. (NCT04535141)
Timeframe: Day 1 to 5 days after end of the chemotherapy (Days 2- 12).

,,,,,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4Grade 5None
Baseline Olanzapine4000041
Baseline Usual Care3000043
Olanzapine Post-chemo Day 13000042
Olanzapine- End of Study3010041
Usual Care End of Study3010042
Usual Care Post-chemo Day 12000044

Severity of Nausea in Delayed Phase

"The severity of nausea in the delayed phase was defined as the response of the subject to the PRO- CTCAE nausea question.~Starting the second day after the completion of highly or moderately emetogenic conditioning chemotherapy and continuing through the fifth day after the completion of highly or moderately emetogenic chemotherapy (PRO-CTCAE) Scale: Never, Rarely, Occasionally, Frequently, Almost constantly~o meet the endpoint, the subject could not have answered a score as higher than mild in the period of time starting 24 hours after the last dose of chemotherapy and continuing until the 5th day following receipt of chemotherapy ." (NCT04535141)
Timeframe: Day 2-12

,
InterventionParticipants (Count of Participants)
Met endpointDid not meet endpoint
Olanzapine3124
Usual Care2323

Overall Percentage of Patients Who Had a Complete Response

Overall percentage of patients who had a complete response (CR) defined as no emesis and minimal nausea (< 25 mm on a 100 mm visual analog scale [VAS]) during the overall assessment period (starting day 1 of chemotherapy and continuing for 5 days after discontinuation of chemotherapy) for the first cycle of chemotherapy. (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo13
Triplet Therapy Plus Olanzapine28

Percent of Participants With no Significant Nausea in Acute Phase

Reported as acute [chemotherapy days]. All assessment with all VAS < 25 mm on days of chemotherapy (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo33
Triplet Therapy Plus Olanzapine39

Percent of Participants With no Significant Nausea in Delayed Phase

Reported for delayed [5 days after chemotherapy administration] All assessment with all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo16
Triplet Therapy Plus Olanzapine34

Percent of Patients Achieving Complete Protection in Overall Assessment Phase

(CP = no emesis, no breakthrough antiemetic use, no significant nausea). To be reported as overall phases [chemotherapy days plus 5 days after] (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo6
Triplet Therapy Plus Olanzapine13

Percent of Patients With Complete Response in Acute Phase

Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in acute phase (days of chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo31
Triplet Therapy Plus Olanzapine39

Percent of Patients With Complete Response in Delayed Phase

Complete response (no emesis and no more than minimal nausea, defined as < 25 mm on a 100 mm visual analog scale [VAS]) in delayed phase (5 days after chemotherapy) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo15
Triplet Therapy Plus Olanzapine31

Percent of Patients With no Nausea in Overall Assessment Period

No nausea (all VAS <5 mm) in overall assessment period (days of chemotherapy plus five days after) (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo6
Triplet Therapy Plus Olanzapine18

Percent of Patients With no Significant Nausea in Overall Assessment Period

Reported for overall phases [chemotherapy days plus 5 days after] where all VAS < 25 mm (NCT02635984)
Timeframe: Until study completion; estimated 1.5 years

InterventionParticipants (Count of Participants)
Triplet Therapy Plus Placebo14
Triplet Therapy Plus Olanzapine30

Trials

14 trials available for carmustine and Emesis

ArticleYear
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe

2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe

2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe

2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fe

2018
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin

2014
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
    Transplantation proceedings, 2011, Volume: 43, Issue:8

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dex

2011
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
    Cancer, 1981, Jan-01, Volume: 47, Issue:1

    Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S

1981
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Clinical Trials as

1982
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
    Cancer, 1995, Dec-01, Volume: 76, Issue:11

    Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combine

1995
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla

1998
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Neoplasma, 2000, Volume: 47, Issue:5

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th

2000
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal

1976
DTIC (NSC-45388) studies in the southwest oncology group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co

1976
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
    Cancer investigation, 1991, Volume: 9, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dru

1991
Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms.
    Urology, 1988, Volume: 31, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as

1988
Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
    American journal of obstetrics and gynecology, 1973, Jul-15, Volume: 116, Issue:6

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Injections, Intravenous; Ova

1973
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
    Cancer, 1974, Volume: 33, Issue:5

    Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr

1974

Other Studies

12 other studies available for carmustine and Emesis

ArticleYear
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2023, Volume: 36, Issue:5

    Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human

2023
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3

    Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2016
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
    Transplantation proceedings, 2009, Volume: 41, Issue:8

    Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma

2009
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
    Journal of neuro-oncology, 1984, Volume: 2, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl

1984
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
    Cancer, 1980, Dec-01, Volume: 46, Issue:11

    Topics: Antineoplastic Agents; Bleomycin; Carmustine; Drug Administration Schedule; Drug Evaluation; Drug Th

1980
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
    Oncology, 1984, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu

1984
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
    Cancer, 1997, May-01, Volume: 79, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb

1997
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Bone marrow transplantation, 1999, Volume: 24, Issue:5

    Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm

1999
Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain.
    Journal of surgical oncology, 1978, Volume: 10, Issue:6

    Topics: Brain Neoplasms; Carmustine; Drug Administration Schedule; Glioblastoma; Humans; Teniposide; Vomitin

1978
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem

1987
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
    Journal of neuro-oncology, 1986, Volume: 3, Issue:4

    Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb

1986
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Oncology, 1974, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc

1974